Page last updated: 2024-12-11

aurachin d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aurachin D: extracted from myxobacterium, Stigmatella aurantiaca strain Sg a15; MF: C25-H33-N-O; MW: 363; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6124753
CHEMBL ID573376
CHEBI ID2921
SCHEMBL ID15094902
SCHEMBL ID16552860
MeSH IDM0148026

Synonyms (21)

Synonym
aurachin d
108354-13-8
chebi:2921 ,
CHEMBL573376
2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]-1h-quinolin-4-one
aurachin-d
4(1h)-quinolinone, 2-methyl-3-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-
SCHEMBL15094902
SCHEMBL16552860
Q27105882
0ni ,
123631-75-4
137078-71-8
2-methyl-3-((2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)quinolin-4(1h)-one
2-methyl-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)quinolin-4-ol
2-methyl-3-((2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)quinolin-4-ol
DTXSID701318443
trienyl]-1h-quinolin-4-one
2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-
2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1,4-dihydroquinolin-4-one
2-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10- trienyl]-1h-quinolin-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
aurachin RE biosynthesis618
aurachin A, B, C and D biosynthesis1026

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1875521Growth inhibition of nonpathogenic Mycobacterium smegmatis mc2155 incubated for 48 hrs under shaking condition
AID436170Antiplasmodial activity against Plasmodium falciparum W2 after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436174Cytotoxicity against mouse L929 cells after 5 days by MTT assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID1875520Antitubercular activity against Mycobacterium tuberculosis mc26230 incubated for 7 days
AID436172Inhibition of respiration in bovine heart submitochondrial particles assessed as NADH oxidation2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436171Antiplasmodial activity against Plasmodium falciparum D6 clone after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID1875519Inhibition of Mycobacterium tuberculosis cytochrome bd oxidase over expressed in inverted membrane vesicles of Mycobacterium smegmatis mc2155 deltacydAB assessed as reduction in malate-induced increase in oxygen consumption rate measured at 120 secs in pr
AID1875522Growth inhibition of Mycobacterium smegmatis mc2155 harboring deltaqcr mutant incubated for 48 hrs under shaking condition
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.26)18.7374
1990's4 (21.05)18.2507
2000's4 (21.05)29.6817
2010's7 (36.84)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.40 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]